Immunohistochemical detection of FGF-23 protein in tumors that cause oncogenic osteomalacia

European Journal of Endocrinology

Volumn 148, Issue 2, 2003, Pages 269-276

  Larsson, Tobias ^a,c   Zahradnik, Richard ^b   Lavigne, Jeffrey ^b   Ljunggren, Östen ^a   Jüppner, Harald ^c   Jonsson, Kenneth B ^a,c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Immutopics International   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CALCITRIOL; COMPLEMENTARY RNA; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; MESSENGER RNA; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY PRODUCTION; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MESENCHYMOMA; ONCOGENIC HYPOPHOSPHATEMIC OSTEOMALACIA; OSTEOMALACIA; PATHOGENESIS; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PURIFICATION; TUMOR BIOPSY; WESTERN BLOTTING;

ADULT; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESENCHYMOMA; MIDDLE AGED; OSTEOMALACIA; RNA, MESSENGER;

EID: 0037295477     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1480269     Document Type: Article

References (22)

1. Ryan EA & Reiss E. Oncogenous osteomalacia. Review of the world literature of 42 cases and report of two new cases. American Journal of Medicine 1984 77 501-512.
2. Nelson AE, Mason RS & Robinson BG. The PEX gene: not a simple answer for X-linked hypophosphataemic rickets and oncogenic osteomalacia. Molecular and Cellular Endocrinology 1997 132 1-5.
3. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nature Genetics 1995 11 130-136.
4. White KE, Jonsson KB, Carn G, Hampson G, Spector TD, Mannstadt M et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. Journal of Clinical Endocrinology and Metabolism 2001 86 497-500.
5. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. PNAS 2001 98 6500-6505.
6. Yamashita T, Yoshioka M & Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochemical and Biophysical Research Communications 2000 277 494-498.
7. Seufert J, Ebert K, Muller J, Eulert J, Hendrich C, Werner E et al. Octreotide therapy for tumor-induced osteomalacia. New England Journal of Medicine 2001 345 1883-1888.
8. Jan de Beur SM, Barberio D, Cook B, Estes S, Finnegan R, Madden S et al. Gene expression profiles of tumors associated with oncogenic osteomalacia. Journal of Bone Mineral Research 2000 15 S357.
9. Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ et al. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 2000 67 54-68.
10. Shimada T, Yoneya T, Hino R, Takeuchi Y, Fukumoto S & Yamashita T. Transgenic mice expressing fibroblast growth factor 23 (FGF23) demonstrate hypophosphatemia with low serum 1,25-dihydroxyvitamin D [1,25(OH)2D] and rickets/osteomalacia. Journal of Bone Mineral Research 2001 16 S151.
11. Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R et al. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochemical and Biophysical Research Communications 2001 284 977-981.
12. Yamashita T, Konishi M, Miyake A, Inui K & Itoh N. Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. Journal of Biological Chemistry 2002 277 28265-28270.
13. Miyauchi A, Fukase M, Tsutsumi M & Fujita T. Hemangiopericytoma-induced osteomalacia: tumor transplantation in nude mice causes hypophosphatemia and tumor extracts inhibit renal 25-hydroxyvitamin D 1-hydroxylase activity. Journal of Clinical Endocrinology and Metabolism 1988 67 46-53.
14. Yang IM, Park YK, Hyun YJ, Kim DY, Woo JT, Kim SW et al. Oncogenic osteomalacia caused by a phosphaturic mesenchymal tumor of the oral cavity: a case report. Korean Journal of Internal Medicine 1997 12 89-95.
15. Nelson AE, Mason RS, Robinson BG, Hogan JJ, Martin EA, Ahlstrom H et al. Diagnosis of a patient with oncogenic osteomalacia using a phosphate uptake bioassay of serum and magnetic resonance imaging. European Journal of Endocrinology 2001 145 469-476.
16. Soegiarto DW, Kiachopoulos S, Schipani E, Juppner H, Erben RG & Lanske B. Partial rescue of PTH/PTHrP receptor knockout mice by targeted expression of the Jansen transgene. Endocrinology 2001 142 5303-5310.
17. Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2002 143 3179-3182.
18. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM & Econs MJ. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney International 2001 60 2079-2086.
19. Sabbagh Y, Jones AO & Tenenhouse HS. PHEXdb, a locus-specific database for mutations causing X-linked hypophosphatemia. Human Mutation 2000 16 1-6.
20. Guo R, Liu S, Spurney RF & Quarles LD. Analysis of recombinant Phex: an endopeptidase in search of a substrate. American Journal of Physiology. Endocrinology and Metabolism 2001 281 E837-E847.
21. Haviv YS & Silver J. Late onset oncogenic osteomalacia-associated with neurofibromatosis type II. Clinical Nephrology 2000 54 429-430.
22. Jonsson KB, Zahradnik R, Larsson T, White KE, Hampson G, Miyauchi A et al. FGF-23 Is a circulating factor that is elevated in oncogenic osteomalacia and X-linked hypophosphatemic rickets. Journal of Bone Mineral Research 2002 17 S158.